We and others have previously shown that blocking the apoE/Aβ interaction by Aβ12-28 P peptides could constitute a novel treatment for AD by reducing brain parenchymal and vascular amyloid burden as well as tau related pathology in several AD transgenic mice lines16–20. This evidence concerns the gene APOE and Alzheimer disease.